{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T13:10:39Z","timestamp":1763644239108,"version":"3.37.3"},"reference-count":167,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.ejmech.2024.116435","type":"journal-article","created":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T05:36:11Z","timestamp":1713591371000},"page":"116435","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Research strategies of small molecules as chemotherapeutics to overcome multiple myeloma resistance"],"prefix":"10.1016","volume":"271","author":[{"given":"Jin","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Cheng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi-Xuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing-Qing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue-Jiao","family":"Leng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiao","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng-Yuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tian-Hua","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Chen","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan-Liang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1589-7442","authenticated-orcid":false,"given":"Nian-Guang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Hao","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2024.116435_bib1","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrc2189","article-title":"Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets","volume":"7","author":"Hideshima","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2024.116435_bib2","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma","volume":"351","author":"Kyle","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2024.116435_bib3","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.drudis.2019.11.008","article-title":"New generation drugs for treatment of multiple myeloma","volume":"25","author":"Alanazi","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2024.116435_bib4","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13045-016-0282-1","article-title":"Novel agents in the treatment of multiple myeloma: a review about the future","volume":"9","author":"Naymagon","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2024.116435_bib5","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.ejmech.2024.116435_bib6","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.ejmech.2024.116435_bib7","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1007\/s40265-020-01404-x","article-title":"Belantamab mafodotin: first approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2024.116435_bib8","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2024.116435_bib9","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3389\/fonc.2014.00241","article-title":"Therapeutic advancements in multiple myeloma","volume":"4","author":"Gozzetti","year":"2014","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2024.116435_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107579","article-title":"The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges","volume":"213","author":"Tundo","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2024.116435_bib11","first-page":"199","article-title":"Drug resistance in multiple myeloma, Cancer Treat","volume":"70","author":"Robak","year":"2018","journal-title":"Rev"},{"key":"10.1016\/j.ejmech.2024.116435_bib12","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/nyas.13038","article-title":"Multiple myeloma in the marrow: pathogenesis and treatments","volume":"1364","author":"Fairfield","year":"2016","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejmech.2024.116435_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cancergen.2020.12.001","article-title":"Genetic variants as biomarkers for progression and resistance in multiple myeloma","volume":"252\u2013253","author":"Montel","year":"2021","journal-title":"Cancer Genet"},{"key":"10.1016\/j.ejmech.2024.116435_bib14","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s12185-022-03353-5","article-title":"Multiple myeloma with high-risk cytogenetics and its treatment approach","volume":"115","author":"Hanamura","year":"2022","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.ejmech.2024.116435_bib15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bjh.15210","article-title":"Resistance to proteasome inhibitors and other targeted therapies in myeloma","volume":"182","author":"Wallington-Beddoe","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejmech.2024.116435_bib16","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/17474086.2020.1711730","article-title":"Heat shock proteins as a new, promising target of multiple myeloma therapy","volume":"13","author":"Grosicki","year":"2020","journal-title":"Expert Rev. Hematol."},{"issue":"14","key":"10.1016\/j.ejmech.2024.116435_bib17","doi-asserted-by":"crossref","first-page":"7627","DOI":"10.3390\/ijms23147627","article-title":"Targeting the microenvironment for treating multiple myeloma","volume":"23","author":"Neumeister","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2024.116435_bib18","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nsmb.2874","article-title":"Structure of the human Cereblon\u2013DDB1\u2013lenalidomide complex reveals basis for responsiveness to thalidomide analogs","volume":"21","author":"Chamberlain","year":"2014","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejmech.2024.116435_bib19","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.ejmech.2024.116435_bib20","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1182\/blood.2019000789","article-title":"Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs","volume":"134","author":"Sperling","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.116435_bib21","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1016\/j.bmcl.2017.07.046","article-title":"Design, synthesis and biological evaluation of Lenalidomide derivatives as tumor angiogenesis inhibitor","volume":"27","author":"Hu","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.116435_bib22","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1182\/blood-2016-02-698092","article-title":"Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes","volume":"128","author":"Kort\u00fcm","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.116435_bib23","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2147\/CMAR.S105163","article-title":"Update on the Optimal Use of Bortezomib in the Treatment of Multiple Myeloma","volume":"9","author":"Mohan","year":"2017","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.ejmech.2024.116435_bib24","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2024.116435_bib25","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.bbrc.2009.03.077","article-title":"MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells","volume":"383","author":"Li","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2024.116435_bib26","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.cellsig.2010.03.003","article-title":"PhosphoMARCKS drives motility of mouse melanoma cells","volume":"22","author":"Chen","year":"2010","journal-title":"Cell. Signal."},{"key":"10.1016\/j.ejmech.2024.116435_bib27","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4049\/jimmunol.1501351","article-title":"The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via fc\u03b3 receptor\u2013mediated cross-linking","volume":"197","author":"Overdijk","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejmech.2024.116435_bib28","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/bjh.15121","article-title":"Current use of monoclonal antibodies in the treatment of multiple myeloma","volume":"181","author":"Varga","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejmech.2024.116435_bib29","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/ejh.13046","article-title":"Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis","volume":"100","author":"Pick","year":"2018","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.ejmech.2024.116435_bib30","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","article-title":"CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.116435_bib31","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00277-018-3465-8","article-title":"Glucocorticoids in multiple myeloma: past, present, and future","volume":"98","author":"Burwick","year":"2019","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.ejmech.2024.116435_bib32","first-page":"199","article-title":"Drug resistance in multiple myeloma, Cancer Treat","volume":"70","author":"Robak","year":"2018","journal-title":"Rev"},{"key":"10.1016\/j.ejmech.2024.116435_bib33","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1038\/leu.2017.54","article-title":"RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma","volume":"31","author":"Viziteu","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2024.116435_bib34","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1038\/s41467-022-31430-0","article-title":"The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma","volume":"13","author":"Vo","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2024.116435_bib35","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","article-title":"Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma","volume":"132","author":"Walker","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.116435_bib36","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abg2697","article-title":"ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment","volume":"7","author":"Liu","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejmech.2024.116435_bib37","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2024.116435_bib38","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/sj.onc.1210204","article-title":"Discovery and development of SAHA as an anticancer agent","volume":"26","author":"Marks","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2024.116435_bib39","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/ijc.23243","article-title":"Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer","volume":"122","author":"Qian","year":"2008","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejmech.2024.116435_bib40","first-page":"8567","volume":"vol. 102","author":"Hideshima","year":"2005"},{"key":"10.1016\/j.ejmech.2024.116435_bib41","first-page":"13162","volume":"vol. 113","author":"Hideshima","year":"2016"},{"key":"10.1016\/j.ejmech.2024.116435_bib42","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1073\/pnas.0430973100","article-title":"Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation","volume":"100","author":"Haggarty","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ejmech.2024.116435_bib43","doi-asserted-by":"crossref","first-page":"10842","DOI":"10.1021\/ja102758v","article-title":"Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A","volume":"132","author":"Butler","year":"2010","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2024.116435_bib44","doi-asserted-by":"crossref","first-page":"8567","DOI":"10.1073\/pnas.0503221102","article-title":"Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma","volume":"102","author":"Hideshima","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ejmech.2024.116435_bib45","doi-asserted-by":"crossref","first-page":"13162","DOI":"10.1073\/pnas.1608067113","article-title":"Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma","volume":"113","author":"Hideshima","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ejmech.2024.116435_bib46","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/s41375-018-0062-8","article-title":"Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors","volume":"32","author":"Bae","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2024.116435_bib47","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1182\/blood-2011-10-387365","article-title":"Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma","volume":"119","author":"Santo","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.116435_bib48","doi-asserted-by":"crossref","first-page":"13459","DOI":"10.1073\/pnas.1718823114","article-title":"Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors","volume":"114","author":"Porter","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ejmech.2024.116435_bib49","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S1470-2045(16)30375-8","article-title":"Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial","volume":"17","author":"Yee","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2024.116435_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.jscs.2022.101450","article-title":"Design, synthesis, and biological evaluation of novel histone deacetylase 6 selective inhibitors","volume":"26","author":"Zhang","year":"2022","journal-title":"J. Saudi Chem. Soc."},{"key":"10.1016\/j.ejmech.2024.116435_bib51","doi-asserted-by":"crossref","first-page":"9891","DOI":"10.1021\/jm301098e","article-title":"Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth","volume":"55","author":"Bergman","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116435_bib52","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nchembio.2140","article-title":"Structural insights into HDAC6 tubulin deacetylation and its selective inhibition","volume":"12","author":"Miyake","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2024.116435_bib53","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20181916","article-title":"The selective HDAC6 inhibitor Nexturastat A induces apoptosis, overcomes drug resistance and inhibits tumor growth in multiple myeloma","volume":"39","author":"Sun","year":"2019","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.ejmech.2024.116435_bib54","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1021\/acs.jmedchem.5b01342","article-title":"Discovery of selective histone deacetylase 6 inhibitors using the quinazoline as the cap for the treatment of cancer","volume":"59","author":"Yang","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116435_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112411","article-title":"PTG-0861: a novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia","volume":"201","author":"Gawel","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116435_bib56","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1021\/acs.jmedchem.7b01404","article-title":"(N-Hydroxycarbonylbenylamino)quinolines as selective histone deacetylase 6 inhibitors suppress growth of multiple myeloma in vitro and in vivo","volume":"61","author":"Lee","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116435_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105278","article-title":"Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity","volume":"116","author":"Li","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2024.116435_bib58","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1021\/acsmedchemlett.9b00084","article-title":"Design, synthesis, and biological evaluation of 2,4-imidazolinedione derivatives as HDAC6 isoform-selective inhibitors","volume":"10","author":"Liang","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.116435_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111950","article-title":"Novel 2, 5-diketopiperazine derivatives as potent selective histone deacetylase 6 inhibitors: rational design, synthesis and antiproliferative activity","volume":"187","author":"Chen","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116435_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113526","article-title":"Design, synthesis and biological evaluation of 3, 4-disubstituted-imidazolidine-2, 5-dione derivatives as HDAC6 selective inhibitors","volume":"221","author":"Liang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116435_bib61","doi-asserted-by":"crossref","first-page":"9090","DOI":"10.1021\/acs.jmedchem.7b00933","article-title":"Small molecule antagonists of the interaction between the histone deacetylase 6 zinc-finger domain and ubiquitin","volume":"60","author":"Harding","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116435_bib62","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1021\/acs.jmedchem.8b00258","article-title":"Identification and structure-activity relationship of HDAC6 zinc-finger ubiquitin binding domain inhibitors","volume":"61","author":"Ferreira de Freitas","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116435_bib63","doi-asserted-by":"crossref","first-page":"13141","DOI":"10.1074\/jbc.R700001200","article-title":"The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation","volume":"282","author":"Wu","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2024.116435_bib64","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","article-title":"Selective inhibition of tumor oncogenes by disruption of super-enhancers","volume":"153","author":"Lov\u00e9n","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2024.116435_bib65","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12943-018-0915-9","article-title":"BRD4 and Cancer: going beyond transcriptional regulation","volume":"17","author":"Donati","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2024.116435_bib66","doi-asserted-by":"crossref","first-page":"4687","DOI":"10.1182\/blood-2023-187762","article-title":"The spop\/BRD4\/c-myc Axis modulates IMiDs sensitivity in multiple myeloma","volume":"142","author":"Xing","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.116435_bib67","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2024.116435_bib68","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2024.116435_bib69","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2013-01-478420","article-title":"Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762","volume":"123","author":"Chaidos","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.116435_bib70","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1021\/acs.jmedchem.5b01882","article-title":"Identification of a benzoisoxazoloazepine inhibitor (CPI-0610) of the bromodomain and extra-terminal (BET) family as a candidate for human clinical trials","volume":"59","author":"Albrecht","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116435_bib71","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1038\/leu.2016.355","article-title":"Preclinical activity of CPI-0610, a novel small-molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma","volume":"31","author":"Siu","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2024.116435_bib72","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41408-021-00545-w","article-title":"A phase 1b dose-escalation\/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma","volume":"11","author":"Ramasamy","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ejmech.2024.116435_bib73","first-page":"e196","article-title":"Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study, the Lancet","volume":"3","author":"Amorim","year":"2016","journal-title":"Haematology"},{"key":"10.1016\/j.ejmech.2024.116435_bib74","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1021\/acs.molpharmaceut.8b00554","article-title":"Potent activity of the bromodomain inhibitor OTX015 in multiple myeloma","volume":"15","author":"Shi","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2024.116435_bib75","article-title":"Safety and efficacy of bromodomain and extra-terminal inhibitors for the treatment of hematological malignancies and solid tumors: a systematic study of clinical trials","volume":"11","author":"Sun","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.116435_bib76","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature14898","article-title":"Transcriptional plasticity promotes primary and acquired resistance to BET inhibition","volume":"525","author":"Rathert","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2024.116435_bib77","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1158\/1078-0432.CCR-16-0453","article-title":"The MAPK pathway regulates intrinsic resistance to BET inhibitors in colorectal cancer","volume":"23","author":"Ma","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116435_bib78","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13046-019-1082-6","article-title":"EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC","volume":"38","author":"Yin","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116435_bib79","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ejmech.2018.11.018","article-title":"Rational design of 5-((1H-imidazole-1-yl)methyl)quinolin-8-ol derivatives as novel bromodomain-containing protein 4 inhibitors","volume":"163","author":"Xing","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116435_bib80","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1016\/j.bmcl.2018.04.020","article-title":"Discovery and optimization of novel constrained pyrrolopyridone BET family inhibitors","volume":"28","author":"Fidanze","year":"2018","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.ejmech.2024.116435_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111633","article-title":"Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins","volume":"182","author":"Chen","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116435_bib82","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/anie.202008625","article-title":"Selective N-terminal BET bromodomain inhibitors by targeting non-conserved residues and structured water displacement","volume":"60","author":"Cui","year":"2021","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2024.116435_bib83","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1021\/acs.jmedchem.1c01779","article-title":"A structure-based design approach for generating high affinity BRD4 D1-selective chemical probes","volume":"65","author":"Cui","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116435_bib84","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12943-023-01721-1","article-title":"Targeting Pim kinases in hematological cancers: molecular and clinical review","volume":"22","author":"Bellon","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2024.116435_bib85","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.3324\/haematol.2009.017079","article-title":"PIM serine\/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers","volume":"95","author":"Brault","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmech.2024.116435_bib86","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1158\/1078-0432.CCR-16-0230","article-title":"The novel pan-PIM kinase inhibitor, PIM447, displays dual antimyeloma and bone-protective effects, and potently synergizes with current standards of care","volume":"23","author":"Pa\u00edno","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116435_bib87","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1182\/blood-2013-01-481457","article-title":"Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation","volume":"122","author":"Lu","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.116435_bib88","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12943-023-01721-1","article-title":"Targeting Pim kinases in hematological cancers: molecular and clinical review","volume":"22","author":"Bellon","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2024.116435_bib89","first-page":"4304","volume":"vol. 13","author":"Wu","year":"2021"},{"key":"10.1016\/j.ejmech.2024.116435_bib90","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1021\/ml400307j","article-title":"Structure guided optimization, in vitro activity, and in vivo activity of pan-PIM kinase inhibitors","volume":"4","author":"Burger","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.116435_bib91","doi-asserted-by":"crossref","first-page":"8373","DOI":"10.1021\/acs.jmedchem.5b01275","volume":"58","author":"Burger","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116435_bib92","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/PPO.0000000000000171","article-title":"Inhibitors of the cyclin-dependent kinase and PIM kinase pathways in the treatment of myeloma","volume":"22","author":"Ramakrishnan","year":"2016","journal-title":"Cancer J."},{"key":"10.1016\/j.ejmech.2024.116435_bib93","doi-asserted-by":"crossref","first-page":"5258","DOI":"10.1016\/j.bmcl.2015.09.052","article-title":"Discovery of 3,5-substituted 6-azaindazoles as potent pan-Pim inhibitors","volume":"25","author":"Hu","year":"2015","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.ejmech.2024.116435_bib94","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.1021\/acs.jmedchem.7b00418","article-title":"Discovery of 5-azaindazole (GNE-955) as a potent pan-pim inhibitor with optimized bioavailability","volume":"60","author":"Wang","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116435_bib95","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1021\/acs.jmedchem.8b01857","article-title":"Optimization of pan-pim kinase activity and oral bioavailability leading to diaminopyrazole (GDC-0339) for the treatment of multiple myeloma","volume":"62","author":"Wang","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116435_bib96","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1021\/acs.jmedchem.8b01733","article-title":"Discovery of (R)-8-(6-Methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4- b]pyrrol-2-yl)-3-(1-methylcyclopropyl)-2-((1-methylcyclopropyl)amino)quinazolin-4(3 H)-one, a potent and selective pim-1\/2 kinase inhibitor for hematological malignancies","volume":"62","author":"Wang","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116435_bib97","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.pharmthera.2011.08.001","article-title":"G protein-coupled receptor kinases: more than just kinases and not only for GPCRs","volume":"133","author":"Gurevich","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2024.116435_bib98","first-page":"1801","article-title":"[Effect of G Protein-coupled receptor kinase 6 on proliferation and apoptosis of multiple myeloma cells and its mechanisms]","volume":"24","author":"Liang","year":"2016","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.ejmech.2024.116435_bib99","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1182\/blood-2009-09-243980","article-title":"Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase","volume":"115","author":"Tiedemann","year":"2010","journal-title":"GRK6, Blood"},{"key":"10.1016\/j.ejmech.2024.116435_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.pep.2021.105890","article-title":"Protein expression and purification of G-protein coupled receptor kinase 6 (GRK6), toward structure-based drug design and discovery for multiple myeloma","volume":"185","author":"Olson","year":"2021","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.ejmech.2024.116435_bib101","doi-asserted-by":"crossref","first-page":"11129","DOI":"10.1021\/acs.jmedchem.1c00506","article-title":"Design, synthesis, and characterization of 4-aminoquinazolines as potent inhibitors of the G protein-coupled receptor kinase 6 (GRK6) for the treatment of multiple myeloma","volume":"64","author":"Uehling","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116435_bib102","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.ejmech.2024.116435_bib103","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1182\/blood-2011-11-390658","article-title":"Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.116435_bib104","doi-asserted-by":"crossref","first-page":"11345","DOI":"10.1158\/0008-5472.CAN-05-2159","article-title":"Mutually exclusive cyclin-dependent kinase 4\/cyclin D1 and cyclin-dependent kinase 6\/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma","volume":"65","author":"Ely","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116435_bib105","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1182\/blood-2014-05-573741","article-title":"Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma","volume":"125","author":"Kumar","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.116435_bib106","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1182\/blood-2010-08-304022","article-title":"RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5","volume":"117","author":"Zhu","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.116435_bib107","doi-asserted-by":"crossref","first-page":"7661","DOI":"10.1158\/0008-5472.CAN-06-1098","article-title":"A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4\/6","volume":"66","author":"Baughn","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116435_bib108","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/s41375-021-01475-z","article-title":"Combination therapy targeting Erk1\/2 and CDK4\/6i in relapsed refractory multiple myeloma","volume":"36","author":"Adamia","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2024.116435_bib109","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13092181","article-title":"Targeting CDK9 for anti-cancer therapeutics","volume":"13","author":"Mandal","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2024.116435_bib110","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.bmcl.2018.01.002","article-title":"Novel compounds with potent CDK9 inhibitory activity for the treatment of myeloma","volume":"28","author":"Czudor","year":"2018","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.ejmech.2024.116435_bib111","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1158\/1078-0432.CCR-14-2549","article-title":"CCR 20th anniversary commentary: in the beginning, there was PS-341","volume":"21","author":"Teicher","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116435_bib112","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1182\/blood-2014-05-578732","article-title":"The Tao of myeloma","volume":"124","author":"Boise","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.116435_bib113","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nchembio.1313","article-title":"Covalent and allosteric inhibitors of the ATPase VCP\/p97 induce cancer cell death","volume":"9","author":"Magnaghi","year":"2013","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2024.116435_bib114","doi-asserted-by":"crossref","first-page":"9480","DOI":"10.1021\/acs.jmedchem.5b01346","article-title":"Discovery of a first-in-class, potent, selective, and orally bioavailable inhibitor of the p97 AAA ATPase (CB-5083)","volume":"58","author":"Zhou","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116435_bib115","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.bbadis.2019.04.003","article-title":"Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma","volume":"1865","author":"Brunnert","year":"2019","journal-title":"Biochim. Biophys. Acta, Mol. Basis Dis."},{"key":"10.1016\/j.ejmech.2024.116435_bib116","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1158\/0008-5472.613.65.2","article-title":"Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia","volume":"65","author":"Xu","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116435_bib117","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.2337\/diabetes.48.8.1667","article-title":"5' AMP-activated protein kinase activation causes GLUT4 translocation in skeletal muscle","volume":"48","author":"Kurth-Kraczek","year":"1999","journal-title":"Diabetes"},{"key":"10.1016\/j.ejmech.2024.116435_bib118","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1158\/1078-0432.CCR-14-1088","article-title":"Targeting the metabolic plasticity of multiple myeloma with FDA-approved ritonavir and metformin","volume":"21","author":"Dalva-Aydemir","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116435_bib119","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ejmech.2017.08.029","article-title":"Development of GLUT4-selective antagonists for multiple myeloma therapy","volume":"139","author":"Wei","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116435_bib120","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1182\/blood-2014-03-557298","article-title":"A critical role of autocrine sonic hedgehog signaling in human CD138+ myeloma cell survival and drug resistance","volume":"124","author":"Liu","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.116435_bib121","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bjh.15210","article-title":"Resistance to proteasome inhibitors and other targeted therapies in myeloma","volume":"182","author":"Wallington-Beddoe","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejmech.2024.116435_bib122","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/978-3-030-38266-7_6","article-title":"Resistance to the proteasome inhibitors: lessons from multiple myeloma and mantle cell lymphoma","volume":"1233","author":"Gonzalez-Santamarta","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ejmech.2024.116435_bib123","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27072201","article-title":"Revisiting proteasome inhibitors: molecular underpinnings of their development, mechanisms of resistance and strategies to overcome anti-cancer drug resistance","volume":"27","author":"Leonardo-Sousa","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2024.116435_bib124","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14081905","article-title":"Metabolic vulnerabilities in multiple myeloma","volume":"14","author":"Lim","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2024.116435_bib125","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1152\/physrev.2001.81.1.153","article-title":"Small GTP-binding proteins","volume":"81","author":"Takai","year":"2001","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejmech.2024.116435_bib126","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1155621","article-title":"Metabolic changes underlying drug resistance in the multiple myeloma tumor microenvironment","volume":"13","author":"Matamala Montoya","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2024.116435_bib127","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1021\/acsmedchemlett.5b00334","article-title":"Potent triazole bisphosphonate inhibitor of geranylgeranyl diphosphate synthase","volume":"6","author":"Wills","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.116435_bib128","doi-asserted-by":"crossref","first-page":"6904","DOI":"10.1021\/acs.jmedchem.8b00886","article-title":"Unraveling the prenylation-cancer paradox in multiple myeloma with novel geranylgeranyl pyrophosphate synthase (GGPPS) inhibitors","volume":"61","author":"Lacbay","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116435_bib129","doi-asserted-by":"crossref","first-page":"6355","DOI":"10.7150\/thno.51286","article-title":"DEPTOR stabilizes ErbB2 to promote the proliferation and survival of ErbB2-positive breast cancer cells","volume":"11","author":"Bi","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.ejmech.2024.116435_bib130","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1182\/blood.V118.21.2916.2916","article-title":"DEPTOR is a regulator of response to mTOR kinase inhibitors in multiple myeloma","volume":"118","author":"Cirstea","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.116435_bib131","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.cell.2009.03.046","article-title":"DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival","volume":"137","author":"Peterson","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2024.116435_bib132","doi-asserted-by":"crossref","first-page":"14942","DOI":"10.1021\/acs.jmedchem.1c00087","article-title":"Design, synthesis, and biological evaluation of Icaritin derivatives as novel putative DEPTOR inhibitors for multiple myeloma treatment","volume":"64","author":"Hou","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116435_bib133","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/nrd3321","article-title":"Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets","volume":"10","author":"Bedford","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2024.116435_bib134","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/imr.12301","article-title":"The E3 ligase Itch in immune regulation and beyond","volume":"266","author":"Aki","year":"2015","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ejmech.2024.116435_bib135","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejmech.2017.09.011","article-title":"1,4-Naphthoquinones as inhibitors of Itch, a HECT domain-E3 ligase, and tumor growth suppressors in multiple myeloma","volume":"140","author":"Liu","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"Suppl 1","key":"10.1016\/j.ejmech.2024.116435_bib136","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2091-9-S1-S1","article-title":"Targeting the UPS as therapy in multiple myeloma","volume":"9","author":"Chauhan","year":"2008","journal-title":"BMC Biochem."},{"key":"10.1016\/j.ejmech.2024.116435_bib137","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1021\/jm801329v","article-title":"Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047)","volume":"52","author":"Zhou","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116435_bib138","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1126\/science.1069490","article-title":"Recruitment of a 19S proteasome subcomplex to an activated promoter","volume":"296","author":"Gonzalez","year":"2002","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.ejmech.2024.116435_bib139","doi-asserted-by":"crossref","first-page":"10230","DOI":"10.1021\/acs.jmedchem.1c00604","article-title":"Structure-based optimization and discovery of M3258, a specific inhibitor of the immunoproteasome subunit LMP7 (beta5i)","volume":"64","author":"Klein","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116435_bib140","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/jcsm.12050","article-title":"Effect of the specific proteasome inhibitor bortezomib on cancer-related muscle wasting","volume":"7","author":"Penna","year":"2016","journal-title":"Journal of cachexia, sarcopenia and muscle"},{"key":"10.1016\/j.ejmech.2024.116435_bib141","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/jphp.12072","article-title":"Carfilzomib: a novel agent for multiple myeloma","volume":"65","author":"Redic","year":"2013","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.116435_bib142","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2022.101536","article-title":"Cardiovascular toxicity of proteasome inhibitors in multiple myeloma therapy","volume":"48","author":"Zheng","year":"2023","journal-title":"Curr. Probl. Cardiol."},{"key":"10.1016\/j.ejmech.2024.116435_bib143","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/leu.2011.282","article-title":"Bisphosphonates as antimyeloma drugs","volume":"26","author":"Modi","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2024.116435_bib144","doi-asserted-by":"crossref","first-page":"6455","DOI":"10.1016\/j.bmcl.2013.09.043","article-title":"Design, synthesis, and biological evaluation of bone-targeted proteasome inhibitors for multiple myeloma","volume":"23","author":"Agyin","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.ejmech.2024.116435_bib145","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116182","article-title":"Discovery of novel tripeptide propylene oxide proteasome inhibitors for the treatment of multiple myeloma","volume":"40","author":"Zhang","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116435_bib146","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115867","article-title":"Optimization of piperidine constructed peptidyl derivatives as proteasome inhibitors","volume":"29","author":"Zhao","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116435_bib147","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115187","article-title":"Design and discovery of novel dipeptide boronic acid ester proteasome inhibitors, an oral slowly-released prodrug for the treatment of multiple myeloma","volume":"250","author":"Wang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116435_bib148","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/jcmm.12279","article-title":"Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma","volume":"18","author":"Kubiczkova","year":"2014","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.ejmech.2024.116435_bib149","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.pharmthera.2017.09.001","article-title":"Immunoproteasome-selective and non-selective inhibitors: a promising approach for the treatment of multiple myeloma","volume":"182","author":"Ettari","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2024.116435_bib150","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41435-020-00109-1","article-title":"Recent insights how combined inhibition of immuno\/proteasome subunits enables therapeutic efficacy","volume":"21","author":"Basler","year":"2020","journal-title":"Genes Immun"},{"key":"10.1016\/j.ejmech.2024.116435_bib151","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1021\/acs.jmedchem.0c02255","article-title":"Design and synthesis of novel epigenetic inhibitors targeting histone deacetylases, DNA methyltransferase 1, and lysine methyltransferase G9a with in vivo efficacy in multiple myeloma","volume":"64","author":"Rabal","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116435_bib152","doi-asserted-by":"crossref","first-page":"10299","DOI":"10.1021\/acs.jmedchem.8b01487","article-title":"Discovery of the first-in-class dual histone deacetylase-proteasome inhibitor","volume":"61","author":"Bhatia","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116435_bib153","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1021\/acs.jmedchem.9b02161","article-title":"Discovery of peptide boronate derivatives as histone deacetylase and proteasome dual inhibitors for overcoming bortezomib resistance of multiple myeloma","volume":"63","author":"Zhou","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116435_bib154","doi-asserted-by":"crossref","first-page":"65627","DOI":"10.18632\/oncotarget.11593","article-title":"Evaluation of in vitro effects of various targeted drugs on plasma cells and putative neoplastic stem cells in patients with multiple myeloma","volume":"7","author":"Blatt","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2024.116435_bib155","doi-asserted-by":"crossref","first-page":"e798","DOI":"10.1038\/cddis.2013.306","article-title":"Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL\/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma","volume":"4","author":"Matthews","year":"2013","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2024.116435_bib156","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2014-03-564534","article-title":"A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis","volume":"124","author":"Chen","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.116435_bib157","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.bmcl.2018.12.052","article-title":"Design, synthesis, and bioactivity evaluation of novel Bcl-2\/HDAC dual-target inhibitors for the treatment of multiple myeloma","volume":"29","author":"Zhou","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.ejmech.2024.116435_bib158","doi-asserted-by":"crossref","first-page":"7042","DOI":"10.1021\/acs.jmedchem.9b00516","article-title":"Development of multifunctional histone deacetylase 6 degraders with potent antimyeloma activity","volume":"62","author":"Wu","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116435_bib159","doi-asserted-by":"crossref","first-page":"7575","DOI":"10.1021\/acs.jmedchem.9b00871","article-title":"Potent and preferential degradation of CDK6 via proteolysis targeting chimera degraders","volume":"62","author":"Su","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116435_bib160","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.117134","article-title":"Design, synthesis, and biological evaluation of BRD4 degraders","volume":"78","author":"Ding","year":"2023","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116435_bib161","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1021\/acs.jmedchem.6b01921","article-title":"A cereblon modulator (CC-220) with improved degradation of Ikaros and Aiolos","volume":"61","author":"Matyskiela","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116435_bib162","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/s41375-019-0620-8","article-title":"Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN","volume":"34","author":"Bjorklund","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2024.116435_bib163","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nature18611","article-title":"A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase","volume":"535","author":"Matyskiela","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2024.116435_bib164","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1021\/acs.jmedchem.6b01911","article-title":"Protein degradation via CRL4(CRBN) ubiquitin ligase: discovery and structure-activity relationships of novel glutarimide analogs that promote degradation of Aiolos and\/or GSPT1","volume":"61","author":"Hansen","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116435_bib165","doi-asserted-by":"crossref","first-page":"6648","DOI":"10.1021\/acs.jmedchem.9b01928","article-title":"Discovery of CRBN E3 ligase modulator CC-92480 for the treatment of relapsed and refractory multiple myeloma","volume":"63","author":"Hansen","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116435_bib166","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1056\/NEJMoa2303194","article-title":"Mezigdomide plus dexamethasone in relapsed and refractory multiple myeloma","volume":"389","author":"Richardson","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2024.116435_bib167","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112912","article-title":"Design, synthesis and biological evaluation of thioether-containing lenalidomide and pomalidomide derivatives with anti-multiple myeloma activity","volume":"209","author":"Wang","year":"2021","journal-title":"Eur. J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424003155?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424003155?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T09:36:15Z","timestamp":1717234575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424003155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":167,"alternative-id":["S0223523424003155"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116435","relation":{},"ISSN":["0223-5234"],"issn-type":[{"type":"print","value":"0223-5234"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Research strategies of small molecules as chemotherapeutics to overcome multiple myeloma resistance","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116435","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116435"}}